المؤلفون: К. V. Menshikov, К. В. Меньшиков

المصدر: Creative surgery and oncology; Том 14, № 1 (2024); 42-51 ; Креативная хирургия и онкология; Том 14, № 1 (2024); 42-51 ; 2076-3093 ; 2307-0501

مصطلحات موضوعية: наноколлоиды, sentinel lymph node, sentinel lymph node biopsy, radioisotope method, indocyanine green, inguinofemoral lymphadenectomy, nanocolloids, сторожевой лимфатический узел, биопсия сторожевого лимфатического узла, радиоизотопный метод, индоцианин зеленый, пахово-бедренная лимфаденэктомия

وصف الملف: application/pdf

العلاقة: https://www.surgonco.ru/jour/article/view/915/590Test; Uzan C., Canlorbe G., Miangon P., Conforti R. Référentiel cancer de la vulve. Paris; 2018.; Siegel R.L., Miller K.D., Wagle N.S., Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. DOI:10.3322/caac.21763; Network NCC. NCCN Clinical Practice Guidelines in oncology for vulvar cancer. NCCN; 2024.; Burger M.P., Hollema H., Emanuels A.G., Krans M., Pras E., Bouma J. The importance of the groin node status for the survival of T1 and T2 vulval carcinoma patients. Gynecol Oncol. 1995;57(3):327–34. DOI:10.1006/gyno.1995.1151; Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7–33. DOI:10.3322/caac.21708; Sedlis A., Homesley H., Bundy B.N., Marshall R., Yordan E., Hacker N., et al. Positive groin lymph nodes in superficial squamous cell vulvar cancer. A Gynecologic Oncology Group Study. Am J Obstet Gynecol. 1987;156(5):1159–64. DOI:10.1016/0002-9378(87)90132-3; Липатов О.Н., Меньшиков К.В., Турсуметов Д.С., Пушкарев А.В., Меньшикова И.А., Липатов Д.О. и др. Сравнительная оценка качества жизни у пациенток после хирургического лечения рака вульвы. Паллиативная медицина и реабилитация. 2020;1:20–4.; Mahner S., Jueckstock J., Hilpert F., Neuser P., Harter P., de Gregorio N., et al. Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 study. J Natl Cancer Inst. 2015;107(3):dju426. DOI:10.1093/jnci/dju426; Brincat M.R., Muscat Baron Y. Sentinel lymph node biopsy in the management of vulvar carcinoma: an evidence-based insight. Int J Gynecol Cancer. 2017;27(8):1769–73. DOI:10.1097/IGC.0000000000001075; Levenback C.F. How safe is sentinel lymph node biopsy in patients with vulvar cancer? J Clin Oncol. 2008;26(6):828–9. DOI:10.1200/JCO.2007.14.7124; Schnürch H.G., Ackermann S., Alt C.D., Barinoff J., Böing C., Dannecker C., et al. Diagnosis, therapy and follow-up care of vulvar cancer and its precursors. Guideline of the DGGG and DKG (S2k-Level, AWMF Registry Number 015/059, November 2015. Geburtshilfe Frauenheilkd. 2016;76(10):1035–49. DOI:10.1055/s-0042-103728; Hampl M., Hantschmann P., Michels W., Hillemanns P.; German Multicenter Study Group. Validation of the accuracy of the sentinel lymph node procedure in patients with vulvar cancer: results of a multicenter study in Germany. Gynecol Oncol. 2008;111(2):282–8. DOI:10.1016/j.ygyno.2008.08.007; Te Grootenhuis N.C., van der Zee A.G., van Doorn H.C., van der Velden J., Vergote I., Zanagnolo V., et al. Sentinel nodes in vulvar cancer: Long-term follow-up of the GROningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V) I. Gynecol Oncol. 2016;140(1):8–14. DOI:10.1016/j.ygyno.2015.09.077; Van der Zee A.G., Oonk M.H., De Hullu J.A., Ansink A.C., Vergote I., Verheijen R.H., et al. Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J Clin Oncol. 2008;26(6):884–9. DOI:10.1200/JCO.2007.14.0566; Ramirez P.T., Levenback C. Long-term outcomes of sentinel node mapping in vulvar cancer: A time to cheer with enthusiasm or pause and question current practice? Gynecol Oncol. 2016;140(1):1–2. DOI:10.1016/j.ygyno.2015.12.013; Cabanas R.M. An approach for the treatment of penile carcinoma. Cancer. 1977;39(2):456–66. DOI:10.1002/1097-0142(197702)39:23.0.co;2-i; Razumova Z., Bizzarri N., Pletnev A., Theofanakis C., Selcuk I., van der Steen-Banasik E., et al. 22nd meeting of the European Society of Gynaecological Oncology (ESGO 2021) report. Int J Gynecol Cancer. 2022;32(11):1363–9. DOI:10.1136/ijgc-2022-003593; Stehman F.B., Bundy B.N., Dvoretsky P.M., Creasman W.T. Early stage I carcinoma of the vulva treated with ipsilateral superficial inguinal lymphadenectomy and modified radical hemivulvectomy: a prospective study of the Gynecologic Oncology Group. Obstet Gynecol. 1992;79(4):490–7. PMID: 1553164; Morton D.L., Wen D.R., Wong J.H., Economou J.S., Cagle L.A., Storm F.K., et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127(4):392–9. DOI:10.1001/archsurg.1992.01420040034005; Balch C.M., Buzaid A.C., Soong S.J., Atkins M.B., Cascinelli N., Coit D.G., et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19(16):3635–48. DOI:10.1200/JCO.2001.19.16.3635; de Hullu J.A., Ansink A.C., Tymstra T., van der Zee A.G. What doctors and patients think about false-negative sentinel lymph nodes in vulvar cancer. J Psychosom Obstet Gynaecol. 2001;22(4):199–203. DOI:10.3109/01674820109049974; Collarino A., Fuoco V., Garganese G., Pereira Arias-Bouda L.M., Perotti G., Manca G., et al. Lymphoscintigraphy and sentinel lymph node biopsy in vulvar carcinoma: update from a European expert panel. Eur J Nucl Med Mol Imaging. 2020;47(5):1261–74. DOI:10.1007/s00259-019-04650-8; Preti M., Borella F., Gallio N., Bertero L., Heller D.S., Vieira-Baptista P., et al. Superficially invasive vulvar squamous cell carcinoma: a 37-year-long experience of a tertiary referral center. Cancers (Basel). 2021;13(15):3859. DOI:10.3390/cancers13153859; Tsopelas C. Particle size analysis of (99m)Tc-labeled and unlabeled antimony trisulfide and rhenium sulfide colloids intended for lymphoscintigraphic application. J Nucl Med. 2001;42(3):460–6. PMID: 11337524; Núñez E.G., Faintuch B.L., Teodoro R., Wiecek D.P., Martinelli J.R., da Silva N.G., et al. Influence of colloid particle profile on sentinel lymph node uptake. Nucl Med Biol. 2009;36(7):741–7. DOI:10.1016/j.nucmedbio.2009.04.009; Jimenez I.R., Roca M., Vega E., García M.L., Benitez A., Bajén M., et al. Particle sizes of colloids to be used in sentinel lymph node radiolocalization. Nucl Med Commun. 2008;29(2):166–72. DOI:10.1097/MNM.0b013e3282f258d9; Mirzaei S., Rodrigues M., Hoffmann B., Knoll P., Riegler-Keil M., Kreuzer W., et al. Sentinel lymph node detection with large human serum albumin colloid particles in breast cancer. Eur J Nucl Med Mol Imaging. 2003;30(6):874–8. DOI:10.1007/s00259-003-1147-8; Meads C., Sutton A.J., Rosenthal A.N., Małysiak S., Kowalska M., Zapalska A., et al. Sentinel lymph node biopsy in vulval cancer: systematic review and meta-analysis. Br J Cancer. 2014;110(12):2837–46. DOI:10.1038/bjc.2014.205; Wilke L.G., McCall L.M., Posther K.E., Whitworth P.W., Reintgen D.S., Leitch A.M., et al. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol. 2006;13(4):491–500. DOI:10.1245/ASO.2006.05.013; Hassanzade M., Attaran M., Treglia G., Yousefi Z., Sadeghi R. Lymphatic mapping and sentinel node biopsy in squamous cell carcinoma of the vulva: systematic review and meta-analysis of the literature. Gynecol Oncol. 2013;130(1):237–45. DOI:10.1016/j.ygyno.2013.04.023; Collège National des Gynécologues et Obstétriciens Français: Réunion du 28 janvier 2005 à lille. J. Gynecol. Obstet. Biol. Reprod. 2005;34(513). DOI:10.1016/S0368-2315(05)82867-4; Giannini A., D’Oria O., Chiofalo B., Bruno V., Baiocco E., Mancini E., et al. The giant steps in surgical downsizing toward a personalized treatment of vulvar cancer. J Obstet Gynaecol Res. 2022;48(3):533–40. DOI:10.1111/jog.15103; Zapardiel I., Alvarez J., Barahona M., Barri P., Boldo A., Bresco P., et al. Utility of intraoperative fluorescence imaging in gynecologic surgery: systematic review and consensus statement. Ann Surg Oncol. 2021;28(6):3266–78. DOI:10.1245/s10434-020-09222-x; Vermersch C., Raia Barjat T., Perrot M., Lima S., Chauleur C. Place of indocyanine green coupled with fluorescence imaging in research of breast cancer sentinel node. Bull Cancer. 2016;103(4):381–8. DOI:10.1016/j.bulcan.2016.01.015; Papadia A., Mueller M.D. ICG-Enhanced Fluorescence-Guided SLN Mapping in Gynecological Malignancies. Tuttlingen: Endo Press; 2018.; Raffone A., Raimondo D., Raspollini A., Oliviero A., Travaglino A., Renzulli F., et al. Comparison between laparoscopic and robotic approach for sentinel lymph node biopsy in endometrial carcinoma women. J Pers Med. 2022;13(1):29. DOI:10.3390/jpm13010029; Verbeek F.P., Tummers Q.R., Rietbergen D.D., Peters A.A., Schaafsma B.E., van de Velde C.J., et al. Sentinel lymph node biopsy in vulvar cancer using combined radioactive and fluorescence guidance. Int J Gynecol Cancer. 2015;25(6):1086–93. DOI:10.1097/IGC.0000000000000419; Hutteman M., van der Vorst J.R., Gaarenstroom K.N., Peters A.A., Mieog J.S., Schaafsma B.E., et al. Optimization of near-infrared fluorescent sentinel lymph node mapping for vulvar cancer. Am J Obstet Gynecol. 2012;206(1):89.e1–5. DOI:10.1016/j.ajog.2011.07.039; Wang T., Xu Y., Shao W., Wang C. Sentinel lymph node mapping: current applications and future perspectives in gynecology malignant tumors. Front Med (Lausanne). 2022;9:922585. DOI:10.3389/fmed.2022.922585; Schaafsma B.E., Verbeek F.P., Peters A.A., van der Vorst J.R., de Kroon C.D., van Poelgeest M.I., et al. Near-infrared fluorescence sentinel lymph node biopsy in vulvar cancer: a randomised comparison of lymphatic tracers. BJOG. 2013;120(6):758–64. DOI:10.1111/1471-0528.12173; Mathéron H.M., van den Berg N.S., Brouwer O.R., Kleinjan G.H., van Driel W.J., Trum J.W., et al. Multimodal surgical guidance towards the sentinel node in vulvar cancer. Gynecol Oncol. 2013;131(3):720–5. DOI:10.1016/j.ygyno.2013.09.007; Prader S., du Bois A., Harter P., Breit E., Schneider S., Baert T., et al. Sentinel lymph node mapping with fluorescent and radioactive tracers in vulvar cancer patients. Arch Gynecol Obstet. 2020;301(3):729–36. DOI:10.1007/s00404-019-05415-2; Broach V., Abu-Rustum N.R., Sonoda Y., Brown C.L., Jewell E., Gardner G., et al. Evolution and outcomes of sentinel lymph node mapping in vulvar cancer. Int J Gynecol Cancer. 2020;30(3):383–6. DOI:10.1136/ijgc-2019-000936; Deken M.M., van Doorn H.C., Verver D., Boogerd L.S.F., de Valk K.S., Rietbergen D.D.D., et al. Near-infrared fluorescence imaging compared to standard sentinel lymph node detection with blue dye in patients with vulvar cancer — a randomized controlled trial. Gynecol Oncol. 2020;159(3):672–80. DOI:10.1016/j.ygyno.2020.09.044; Benmoulay-Rigollot C., Karpathiou G., Prevot-Bitot N., Heinemann M., Trombert-Paviot B., Barjat T., et al. Performance of indocyanine green compared to 99mTc-nanocolloids for sentinel lymph node detection in early vulvar cancer. Curr. Oncol. 2022;29:8084–92. DOI:10.3390/curroncol29110638; Soergel P., Hertel H., Nacke A.K., Klapdor R., Derlin T., Hillemanns P. Sentinel lymphadenectomy in vulvar cancer using near-infrared fluorescence from indocyanine green compared with technetium 99m nanocolloid. Int J Gynecol Cancer. 2017;27(4):805–12. DOI:10.1097/IGC.0000000000000996; Crosbie E.J., Winter-Roach B., Sengupta P., Sikand K.A., Carrington B., Murby B., et al. The accuracy of the sentinel node procedure after excision biopsy in squamous cell carcinoma of the vulva. Surg Oncol. 2010;19(4):e150–4. DOI:10.1016/j.suronc.2010.08.003; Milliken S., May J., Sanderson P.A., Congiu M.A., D’Oria O., Golia D’Augè T., et al. Reducing the radicality of surgery for vulvar cancer: are smaller margins safer? Minerva Obstet Gynecol. 2021;73(2):160–5. DOI:10.23736/S2724-606X.20.04743-7; https://www.surgonco.ru/jour/article/view/915Test

الإتاحة: https://doi.org/10.24060/2076-3093-2024-14-1-42-51Test
https://doi.org/10.3322/caac.21763Test
https://doi.org/10.1006/gyno.1995.1151Test
https://doi.org/10.3322/caac.21708Test
https://doi.org/10.1016/0002-9378Test(87)90132-3
https://doi.org/10.1093/jnci/dju426Test
https://doi.org/10.1097/IGC.0000000000001075Test
https://doi.org/10.1055/s-0042-103728Test
https://doi.org/10.1016/j.ygyno.2008.08.007Test
https://doi.org/10.1016/j.ygyno.2015.09.077Test

المؤلفون: G. A. Serebrennikov, К. V. Menshikov, A. V. Sultanbaev, Sh. I. Musin, I. A. Menshikova, N. I. Sultanbaeva, D. O. Lipatov, A. Sh. Rezyapova, Г. А. Серебренников, К. В. Меньшиков, А. В. Султанбаев, Ш. И. Мусин, И. А. Меньшикова, Н. И. Султанбаева, Д. О. Липатов, А. Ш. Резяпова

المساهمون: This work is not funded, Данная работа не финансировалась

المصدر: Creative surgery and oncology; Том 13, № 2 (2023); 131-142 ; Креативная хирургия и онкология; Том 13, № 2 (2023); 131-142 ; 2076-3093 ; 2307-0501

مصطلحات موضوعية: ингибиторы иммунных контрольных точек, liver neoplasms, clinical practice, atezolizumab, bevacizumab, clinical trials, randomized controlled clinical trial, immune checkpoint inhibitors, новообразования печени, клиническая практика, атезолизумаб, бевацизумаб, клинические исследования, рандомизированное контролируемое клиническое исследование

وصف الملف: application/pdf

العلاقة: https://www.surgonco.ru/jour/article/view/810/547Test; Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019; 380 (15): 1450–62. DOI:10.1056/NEJMra1713263; Ахметгареева К. Т., Липатов О. Н., Меньшиков К. В., Султанбаев А. В. Заболеваемость первичным раком печени в Республике Башкортостан. В кн.: Белые ночи 2020 : тезисы VI Петербургского международного онкологического форума. СПб; 2020. С. 22.; Xie Y. Hepatitis B virus-associated hepatocellular carcinoma. Adv Exp Med Biol. 2017; 1018: 11–21. DOI:10.1007/978-981-10-5765-6_2; Kanwal F., Kramer J. R., Mapakshi S., Natarajan Y., Chayanupatkul M., Richardson P. A., et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology. 2018; 155 (6): 1828–37.e2. DOI:10.1053/j.gastro.2018.08.024; Меньшиков К. В., Султанбаев А. В., Мусин Ш. И., Рахматуллина И. Р., Меньшикова И. А., Абдеев Р. Р. и др. Гепатоцеллюлярная карцинома: этиологические факторы и механизмы развития. Обзор литературы. Креативная хирургия и онкология. 2022; 12 (2): 139–50. DOI:10.24060/2076-3093-2022-12-2-139-150; Llovet J. M., Villanueva A., Lachenmayer A., Finn R. S. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol. 2015; 12 (7): 408–24. DOI:10.1038/nrclinonc.2015.103; Cheng A. L., Kang Y. K., Chen Z., Tsao C. J., Qin S., Kim J. S., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, doubleblind, placebo-controlled trial. Lancet Oncol. 2009; 10 (1): 25–34. DOI:10.1016/S1470-2045(08)70285-7; Llovet J. M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J. F., et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359 (4): 378–90. DOI:10.1056/NEJMoa0708857; Меньшиков К. В., Султанбаев А. В., Мусин Ш. И., Меньшикова И. A., Абдеев Р. Р., Султанбаева Н. И. и др. Иммунотерапия распространенной гепатоцеллюлярной карциномы : обзор литературы и клинический случай. Медицинский совет. 2022; 16 (9): 31–9. DOI:10.21518/2079-701X-2022-16-9-31-39; Kudo M., Finn R. S., Qin S., Han K. H., Ikeda K., Piscaglia F., et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018; 391 (10126): 1163–73. DOI:10.1016/S0140-6736(18)30207-1; Bruix J., Qin S., Merle P., Granito A., Huang Y. H., Bodoky G., et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017; 389 (10064): 56–66. DOI:10.1016/S0140-6736(16)32453-9; Меньшиков К. В., Султанбаев А. В., Ахметгареева К. Т., Липатов Д. О. Лечение метастатического гепатоцеллюлярного рака ленватинибом. Клинический случай и обзор литературы. Современная онкология. 2021; 23 (1): 156–61. DOI:10.26442/18151434.2021.1.200785; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018; 69 (1): 182–236. DOI:10.1016/j.jhep.2018.03.019; Heimbach J. K., Kulik L. M., Finn R. S., Sirlin C. B., Abecassis M. M., Roberts L. R., et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018; 67 (1): 358–80. DOI:10.1002/hep.29086; Matsui J., Yamamoto Y., Funahashi Y., Tsuruoka A., Watanabe T., Wakabayashi T., et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008; 122 (3): 664–71. DOI:10.1002/ijc.23131; Tamai T., Hayato S., Hojo S., Suzuki T., Okusaka T., Ikeda K., et al. Dose finding of lenvatinib in subjects with advanced hepatocellular carcinoma based on population pharmacokinetic and exposure-response analyses. J Clin Pharmacol. 2017; 57 (9): 1138–47. DOI:10.1002/jcph.917; Finn R. S., Ikeda M., Zhu A. X., Sung M. W., Baron A. D., Kudo M., et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020; 38 (26): 2960–70. DOI:10.1200/JCO.20.00808; Pishvaian M. J., Lee M. S., Ryoo B.-Y., Stein S., Lee K-H., Verret W., et al. Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC). Ann Oncol. 2018; 29 (Suppl.8): 718–9.; Finn R. S., Qin S., Ikeda M., Galle P. R., Ducreux M., Kim T. Y., et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020; 382 (20): 1894–905. DOI:10.1056/NEJMoa1915745; Giannini E. G., Aglitti A., Borzio M., Gambato M., Guarino M., Iavarone M., et al. Overview of immune checkpoint inhibitors therapy for hepatocellular carcinoma, and The ITA.LI.CA Cohort derived estimate of amenability rate to immune checkpoint inhibitors in clinical practice. Cancers (Basel). 2019;11(11):1689. DOI:10.3390/cancers11111689; Gordan J. D., Kennedy E. B., Abou-Alfa G. K., Beg M. S., Brower S. T., Gade T. P., et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO Guideline. J Clin Oncol. 2020; 38 (36): 4317–45. DOI:10.1200/JCO.20.02672; de Castro T., Jochheim L. S., Bathon M., Welland S., Scheiner B., Shmanko K., et al. Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience. Ther Adv Med Oncol. 2022; 14: 17588359221080298. DOI:10.1177/17588359221080298; Hatanaka T., Kakizaki S., Hiraoka A., Tada T., Hirooka M., Kariyama K., et al. Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non-viral infection: A Japanese multicenter observational study. Cancer Med. 2023; 12 (5): 5293–303. DOI:10.1002/cam4.5337; Shimose S., Hiraoka A., Nakano M., Iwamoto H., Tanaka M., Tanaka T., et al. First-line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study. Cancer Med. 2021; 10 (23): 8530–41. DOI:10.1002/cam4.4367; Hatanaka T., Kakizaki S., Nagashima T., Namikawa M., Ueno T., Tojima H., et al. Lenvatinib for hepatocellular carcinoma patients with nonviral infection who were unlikely to respond to immunotherapy: a retrospective, comparative study. Oncology. 2021; 99 (10): 641–51. DOI:10.1159/000517494; Tsuchiya K., Kurosaki M., Sakamoto A., Marusawa H., Kojima Y., Hasebe C., et al. The real-world data in japanese patients with unresectable hepatocellular carcinoma treated with lenvatinib from a nationwide multicenter study. Cancers (Basel). 2021; 13 (11): 2608. DOI:10.3390/cancers13112608; Hiraoka A., Kumada T., Tada T., Tani J., Kariyama K., Fukunishi S., et al. Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study. Sci Rep. 2021; 11 (1): 16663. DOI:10.1038/s41598-021-96089-x; Tomonari T., Sato Y., Tanaka H., Mitsuhashi T., Hirao A., Tanaka T., et al. Th erapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma. JGH Open. 2021; 5 (11): 1275–83. DOI:10.1002/jgh3.12663; Pugh R. N., Murray-Lyon I. M., Dawson J. L., Pietroni M. C., Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973; 60 (8): 646–9. DOI:10.1002/bjs.1800600817; Tada T., Kumada T., Hiraoka A., Hirooka M., Kariyama K., Tani J., et al. Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis. Cancer Med. 2022; 11 (20): 3796–808. DOI:10.1002/cam4.4763; Singal A. G., Lampertico P., Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: New trends. J Hepatol. 2020; 72 (2): 250–61. DOI:10.1016/j.jhep.2019.08.025; Global Burden of Disease Liver Cancer Collaboration; Akinyemiju T., Abera S., Ahmed M., Alam N., Alemayohu M. A., Allen C., et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol. 2017; 3 (12): 1683–91. DOI:10.1001/jamaoncol.2017.3055; Kumada T., Toyoda H., Tada T., Yasuda S., Tanaka J. Changes in background liver function in patients with hepatocellular carcinoma over 30 years: comparison of child-pugh classification and albumin bilirubin grade. Liver Cancer. 2020; 9 (5): 518–28. DOI:10.1159/000507933; Johnson P. J., Berhane S., Kagebayashi C., Satomura S., Teng M., Reeves H. L., et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015; 33 (6): 550–8. DOI:10.1200/JCO.2014.57.9151; Iwamoto H., Shimose S., Noda Y., Shirono T., Niizeki T., Nakano M., et al. Initial experience of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in real-world clinical practice. Cancers (Basel). 2021; 13 (11): 2786. DOI:10.3390/cancers13112786; Finn R. S., Ryoo B. Y., Merle P., Kudo M., Bouattour M., Lim H. Y., et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol. 2020; 38 (3): 193–202. DOI:10.1200/JCO.19.01307; Yau T., Park J. W., Finn R. S., Cheng A. L., Mathurin P., Edeline J., et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022; 23 (1): 77–90. DOI:10.1016/S1470-2045(21)00604-5; Cheng A. L., Qin S., Ikeda M., Galle P. R., Ducreux M., Kim T. Y., et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022; 76 (4): 862–73. DOI:10.1016/j.jhep.2021.11.030; Finn R. S., Qin S., Ikeda M., Galle P. R., Ducreux M., Kim T.-Y., et al. IMbrave150: Updated Overall Survival (OS) Data from a Global, Randomized, Open-Label Phase III Study of Atezolizumab (Atezo) + Bevacizumab (Bev) versus Sorafenib (Sor) in Patients (Pts) with Unresectable Hepatocellular Carcinoma (HCC). J Clin Oncol. 2021; 39 (3S): 267. DOI:10.1200/JCO.2021.39.3_suppl.267; Galle P. R., Finn R. S., Qin S., Ikeda M., Zhu A. X., Kim T. Y., et al. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021; 22 (7): 991–1001. DOI:10.1016/S1470-2045(21)00151-0; Eisenhauer E. A., Therasse P., Bogaerts J., Schwartz L. H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45 (2): 228–47. DOI:10.1016/j.ejca.2008.10.026; Lencioni R., Llovet J. M. Modifi ed RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010; 30 (1): 52–60. DOI:10.1055/s-0030-1247132; Common Terminology Criteria for Adverse Events v4.0 (CTCAE). Bethesda; 2009.; Common Terminology Criteria for Adverse Events (CTCAE). v.5.0; Cancer Therapy Evaluation Program (CTEP). Rockville; 2017.; Himmelsbach V., Pinter M., Scheiner B., Venerito M., Sinner F., Zimpel C., et al. Efficacy and safety of atezolizumab and bevacizumab in the real-world treatment of advanced hepatocellular carcinoma: experience from four tertiary centers. Cancers (Basel). 2022; 14 (7): 1722. DOI:10.3390/cancers14071722; Qin S., Ren Z., Feng Y. H., Yau T., Wang B., Zhao H., et al. Atezolizumab plus bevacizumab versus sorafenib in the chinese subpopulation with unresectable hepatocellular carcinoma: phase 3 randomized, open-label IMbrave150 study. Liver Cancer. 2021; 10 (4): 296–308. DOI:10.1159/000513486; Pfister D., Núñez N. G., Pinyol R., Govaere O., Pinter M., Szydlowska M., et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021; 592 (7854): 450–6. DOI:10.1038/s41586-021-03362-0; Inada Y., Mizukoshi E., Seike T., Tamai T., Iida N., Kitahara M., et al. Characteristics of immune response to tumor-associated antigens and immune cell profile in patients with hepatocellular carcinoma. Hepatology. 2019; 69 (2): 653–65. DOI:10.1002/hep.30212; https://www.surgonco.ru/jour/article/view/810Test

الإتاحة: https://doi.org/10.24060/2076-3093-2023-13-2-131-142Test
https://doi.org/10.1056/NEJMra1713263Test
https://doi.org/10.1007/978-981-10-5765-6_2Test
https://doi.org/10.1053/j.gastro.2018.08.024Test
https://doi.org/10.24060/2076-3093-2022-12-2-139-150Test
https://doi.org/10.1038/nrclinonc.2015.103Test
https://doi.org/10.1016/S1470-2045Test(08)70285-7
https://doi.org/10.1056/NEJMoa0708857Test
https://doi.org/10.21518/2079-701X-2022-16-9-31-39Test
https://doi.org/10.1016/S0140-6736Test(18)30207-1

المؤلفون: К. V. Menshikov, А. А. Izmaylov, Sh. I. Musin, А. V. Sultanbaev

المصدر: Russian Journal of Oncology. 25:67-71

مصطلحات موضوعية: medicine.medical_specialty, Leukopenia, Coronavirus disease 2019 (COVID-19), business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), General Medicine, Esophageal cancer, medicine.disease, Gastroenterology, Risk groups, Viral pneumonia, Internal medicine, medicine, Clinical case, medicine.symptom, business, Chemoradiotherapy

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::2b0e350225b0f863f8accd91b1a43dfdTest
https://doi.org/10.17816/1028-9984-2020-25-2-67-71Test